InterMune's Esbriet gets OK from EU CHMP: launch expected 3Q11
This article was originally published in Scrip
InterMune's Esbriet (pirfenidone) received a positive opinion by the EU's Committee for Medicinal Products for Human Use (CHMP), the first European approval for any drug to treat mild-to-moderate idiopathic pulmonary fibrosis (IPF). In a conference call, the company CEO and President, Dan Welch, said that the company anticipated a price band for the product of $40,000-45,000 and that the product would be launched in the five largest European national markets – Germany, France, Italy, Spain and the UK – by mid 2012, with the first launch in Germany scheduled for the third quarter of 2011.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.